Why Is COMPASS PATHWAYS ADR ADR (CMPS) Stock Down Today?
By the Top Tier Newswire AI Desk · September 10, 2026 at 10:16 AM ET · reviewed against 9 wire stories
COMPASS PATHWAYS ADR ADR (CMPS) is down -6.66% in the latest session. Our newswire has captured 9 stories on CMPS across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Compass Pathways ADR (CMPS) fell 6.66% to $14.16 on Tuesday, marking a sharp reversal from its recent 14.3% gain over the past eight sessions. The stock opened with a modest 1.8% gap up but quickly declined throughout the session, hitting a low of $14.11 before closing near that level. The move followed the release of 52-week results from its Phase 3 COMP005 trial of COMP360 for treatment-resistant depression, which showed additional benefits but failed to sustain investor confidence.
What Happened
Compass Pathways reported that patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks. The company also announced the selection of Fluence to develop post-approval provider training for COMP360, pending FDA approval. Despite these developments, the stock declined sharply, with volume reaching 0.7 million shares, or 20% of its 3-month average. The stock has now printed 13 fresh 52-week lows on September 10, indicating growing retail and institutional skepticism.
Retail traders on r/wallstreetbets are calling the stock oversold, with some suggesting a rebound to $30, but no immediate catalyst has emerged to support such a move. Management is scheduled to participate in investor conferences the week of September 14, which may provide further clarity on the company’s path forward.
What The Data Shows
The stock is currently trading within its 52-week range of $4.82 to $15.87, near its 52-week low. With a market cap of $1.9 billion and a beta of 2.55, CMPS remains highly volatile. The company is unprofitable, with a trailing 12-month EPS of -3.61. Despite the recent trial data, the stock’s performance suggests investors are pricing in continued uncertainty around regulatory approval and commercial viability.
What To Watch
The week of September 14 features Compass Pathways management’s participation in three New York healthcare investor conferences. These events may offer further insight into the company’s strategy for the U.S. launch of COMP360, pending FDA approval. Investors will also monitor the coverage breadth of the recent trial data and how it influences analyst sentiment in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CMPS · Sep 10 session (5-min) · -6.26% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 9 stories · 62/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoPR NewswireBULLISH 63Product/PR
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been...
3d agoStockTitanBULLISH 56Product/PR
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Compass expanded three planned grants to five after a competitive review; awardees retain control of training content as the U.S. launch remains subject to approval.
3d agoStockTitanBULLISH 56General
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Management's fireside chats run Sept. 15-17 at three New York healthcare conferences; live audio and 30-day replays will be on Compass's Investors page.
3d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Oppenheimer reiterates Compass Pathways stock rating on trial data
Oppenheimer reiterates Compass Pathways stock rating on trial data
3d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Jefferies reiterates Compass Pathways stock rating on TRD approval confidence
Jefferies reiterates Compass Pathways stock rating on TRD approval confidence
3d agoInvesting.com Analyst RatingsBULLISH 67Product/PR
Compass Pathways stock shows durable results in depression trial
Compass Pathways stock shows durable results in depression trial
3d agoStocktwits NewsBULLISH 73Product/PR
CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch
Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.
4d agoThe FlyBULLISH 59Product/PR
Compass Pathways reports 52-week results from Phase 3 COMP005 trial
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →